IQWiG finds no added benefit for Xalkori

13 January 2017

In an early benefit assessment the German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether crizotinib offers advantages for patients over the appropriate comparator therapies.

The drug from US pharma giant Pfizer (NYSE: PFE), marketed as Xalkori, has been approved in Europe since August 2016 for adults with advanced non-small cell lung cancer (NSCLC) in whom the structure of the enzyme “proto-oncogene tyrosine-protein kinase” (ROS1) is altered in the tumor tissue.

According to the findings, such an added benefit is not proven: for one patient group, the dossier does not contain any data at all; for two further groups, the data are unsuitable for assessment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK